Show simple item record

dc.contributor.authorNagot, Nicolas
dc.contributor.authorSingata-Madliki, Mandisa
dc.contributor.authorCournil, Amandine
dc.contributor.authorNalugya, Joyce
dc.contributor.authorTassembedo, Soleymane
dc.contributor.authorQuillet, Catherine
dc.contributor.authorTonga, Melany W.
dc.contributor.authorTumwine, James K
dc.contributor.authorMeda, Nicolas
dc.contributor.authorKankasa, Chipepo
dc.contributor.authorMwiya, Mwiya
dc.contributor.authorBangirana, Paul
dc.contributor.authorPeries, Marianne
dc.contributor.authorBatting, Joanne
dc.contributor.authorEngebretsen, Ingunn Marie Stadskleiv
dc.contributor.authorTylleskär, Thorkild
dc.contributor.authorVan de Perre, Philippe
dc.contributor.authorNdeezi, Grace
dc.contributor.authorMolès, Jean-Pierre
dc.description.abstractIn the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. Between February 2017 and February 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not HIV-infected. In addition to clinical examination, neuropsychological outcomes were assessed using the tests Kaufman-ABCII, Test of Variables of Attention, Movement Assessment Battery for Children and the Strengths and Difficulties questionnaire, parent version. Of 1101 eligible children, aged 5–7 years, 553 could be traced and analysed (274 in the LPV/r and 279 in the 3TC groups). Growth, clinical and neuropsychological outcomes did not differ between treatment groups. At school age, children exposed to LPV/r and 3TC at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral drug in early life.en_US
dc.publisherNature Researchen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleGrowth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1‑year lamivudine or lopinavir/ritonavir HIV prophylaxis in early lifeen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright The Author(s) 2021en_US
dc.source.journalScientific Reportsen_US
dc.identifier.citationScientific Reports. 2021, 11, 3173.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal